Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

Multiple Sclerosis

Volumn 21, Issue 8, 2015, Pages 1025-1035

  Kieseier, Bernd C ^a   Arnold, Douglas L ^b,c   Balcer, Laura J ^d   Boyko, Alexey A ^e   Pelletier, Jean ^f   Liu, Shifang ^g   Zhu, Ying ^g   Seddighzadeh, Ali ^g   Hung, Serena ^g   Deykin, Aaron ^g   Sheikh, Sarah I ^g   Calabresi, Peter A ^h  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MCGILL UNIVERSITY   (Canada)

^c NEURORX RESEARCH   (Canada)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Moscow MS Center 11 City Hospital Department of Neurology and Neurosurgery of the RSMRU   (Russian Federation)

^f AIX MARSEILLE UNIVERSITY   (France)

^g BIOGEN   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Interferon; MRI; multiple sclerosis; peginterferon beta 1a; pegylated; phase 3; relapse; relapse remitting multiple sclerosis

Indexed keywords

PEGINTERFERON BETA1A; PLACEBO; BETA INTERFERON; MACROGOL DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASPIRATION PNEUMONIA; ASTHENIA; BACKACHE; CHILL; CONTROLLED STUDY; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOGENICITY; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; LIMB PAIN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEPTICEMIA; SQUAMOUS CELL CARCINOMA; SUBARACHNOID HEMORRHAGE; THERAPY DELAY; TREATMENT DURATION; TREATMENT WITHDRAWAL; ADOLESCENT; CLINICAL TRIAL; DISABILITY; FEMALE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT; EXPANDED DISABILITY STATUS SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAPSE;

ADOLESCENT; ADULT; AGED; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYETHYLENE GLYCOLS; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937032543     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514557986     Document Type: Article

References (17)

1. Jain A, Jain SK,. PEGylation: An approach for drug delivery. A review. Crit Rev Ther Drug Carrier Syst 2008; 25: 403-447.
2. Baker DP, Lin EY, Lin K,. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem 2006; 17: 179-188.
3. Hu X, Miller L, Richman S,. A novel PEGylated interferon beta-1a for multiple sclerosis: Safety, pharmacology, and biology. J Clin Pharmacol 2012; 52: 798-808.
4. Caliceti P, Veronese FM., Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003; 55: 1261-1277.
5. Kieseier BC, Calabresi PA., PEGylation of interferon-beta-1a: A promising strategy in multiple sclerosis. CNS Drugs 2012; 26: 205-214.
6. Calabresi PA, Kieseier BC, Arnold DL,. Pegylated interferon beta-1a in relapsing-remitting multiple sclerosis: Results from ADVANCE, a randomized, phase 3, double-blind study. Lancet Neurol 2014; 13: 657-665.
7. Polman CH, Reingold SC, Edan G,. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria�. Ann Neurol 2005; 58: 840-846.
8. Kurtzke JF., Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.
9. Polman CH, Bertolotto A, Deisenhammer F,. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740-750.
10. Bertolotto A, Deisenhammer F, Gallo P,. Immunogenicity of interferon beta: Differences among products. J Neurol 2004; 251 (Suppl 2): II15-II24.
11. Paolicelli D, DOnghia M, Pellegrini F,. The impact of neutralizing antibodies on the risk of disease worsening in interferon beta-treated relapsing multiple sclerosis: A 5 year post-marketing study. J Neurol 2013; 260: 1562-1568.
12. Johnson KP, Brooks BR, Cohen JA,. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276.
13. Jacobs LD, Cookfair DL, Rudick RA,. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
14. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
15. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
16. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.
17. Paty DW, Li DK,. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662-667.